Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02387762 · ClinicalTrials.gov registry record · Phase 2

ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

A Phase 2 study of Rheumatoid Arthritis, sponsored by Acerta Pharma.

Completed
Registry status
Phase 2
Development phase
31
Enrollment target
17
Study locations

NCT02387762 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Acerta Pharma. The registered enrollment target is 31 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 17 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02387762, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Acerta Pharma.

COMPLETED
Registry status
Phase 2
Development phase
31 participants
Enrollment target
17
Study locations

Study Summary

This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of ACP-196 in subjects with Rheumatoid Arthritis on background Methotrexate.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG Placebo
  • DRUG acalabrutinib

Study Locations (17)

California

  • TriWest Research Associates, LLC - El Cajon
  • Neuropsychiatric Research Center of Orange County - Orange
  • Pacific Arthritis Center Medical Group - Santa Monica
  • Inland Rheumatology and Osteoporosis Medical Group, Inc - Upland

Florida

  • San Marcus Research Clinic, Inc. - Hialeah
  • Suncoast Clinical Research, Inc. - New Port Richey
  • Suncoast Clinical Research - New Port Richey
  • The Arthritis Center - Palm Harbor

Alabama

  • Pinnacle Research Group - Anniston
  • Achieve Clinical Research - Birmingham

Arizona

  • Advanced Arthritis Care and Research - Scottsdale

Nevada

  • Office of George Timothy Kelly, MD - Las Vegas

North Carolina

  • PMG Research of Salisbury - Salisbury

Oklahoma

  • Health Research of Oklahoma - Oklahoma City

Pennsylvania

  • Altoona Center for Clinical Research - Duncansville

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2015-04
Est. Completion 2016-06
Phase Phase 2

Sponsor

Acerta Pharma

38 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02387762

The ClinicalTrials.gov registry entry for NCT02387762 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The listed sponsor is Acerta Pharma, which has 38 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02387762 reports 17 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT02387762 about?

NCT02387762 is a clinical study titled "ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate". This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of ACP-196 in subjects with Rheumatoid Arthritis on background Methotrexate.

What is the current status of trial NCT02387762?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2015-04. Estimated completion is 2016-06.

What conditions does trial NCT02387762 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT02387762?

The interventions under investigation include: Placebo (DRUG), acalabrutinib (DRUG).

Who is sponsoring clinical trial NCT02387762?

This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02387762 being conducted?

This trial has 17 study locations across Alabama, Arizona, California, Florida, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.